Pre-Open Stock Movers 03/15: (MDCA) (KPTI) (AVGO) Higher; (ASNA) (KOPN) (HEAR) Lower (more...)

March 15, 2019 9:25 AM

Today's Pre-Open Movers

MDC Partners Inc. (NASDAQ: MDCA) 23.2% HIGHER; announced today that it has entered into an agreement with The Stagwell Group pursuant to which Stagwell, a private equity firm that manages investments in new media and digital marketing services, has invested $100 million in MDC Partners through the purchase of $50 million in MDC Partners common shares and $50 million non-voting convertible preference shares. In connection with the transaction, industry veteran Mark Penn will join MDC Partners as Chief Executive Officer and a member of its Board of Directors.

Ascena Retail Group (NASDAQ: ASNA) 22.2% LOWER; reported Q2 EPS of ($0.26), in-line with the analyst estimate of ($0.26). Revenue for the quarter came in at $1.7 billion versus the consensus estimate of $1.71 billion. Ascena Retail Group sees Q3 2019 EPS of ($0.35)-($0.45), versus the consensus of $0.02. Ascena Retail Group sees Q3 2019 revenue of $1.43-1.46 billion, versus the consensus of $1.52 billion.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) 21.6% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) action date for the New Drug Application (NDA) for selinexor. The NDA, which is currently under Priority Review by the FDA, is seeking accelerated approval for selinexor in combination with dexamethasone for the treatment of patients with relapsed refractory multiple myeloma who have received at least three prior therapies and whose disease is refractory to at least one proteasome inhibitor (PI), one immunomodulatory agent (IMiD), and one anti-CD38 monoclonal antibody. The previously disclosed April 6, 2019 PDUFA date has been extended by three months to July 6, 2019.

BioScrip, Inc. (NASDAQ: BIOS) 18.3% HIGHER; BioScrip and Option Care Enterprises, Inc. (Option Care), the nations largest independent providers of home and alternate treatment site infusion therapy services, today announced that they have entered into a definitive merger agreement. The combination is expected to create a leading independent provider with the national reach, comprehensive therapy offering and financial capacity to succeed in the attractive and growing home and alternate site infusion services segment of the $100 billion U.S. infusion market.

Kopin Corporation (Nasdaq: KOPN) 16.1% LOWER; announced that it has commenced an underwritten public offering of its common stock. All shares of common stock to be sold in the offering will be offered by Kopin. Kopin expects to grant to the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering to cover overallotments, if any. The offering is subject to market and other conditions, and there can be no assurances as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

BioTime (NYSE: BTX) 12.3% LOWER; reported Q4 EPS of ($0.35), versus ($0.58) reported last year. Revenue for the quarter came in at $758 thousand, versus $999 thousand reported last year.

Turtle Beach (NASDAQ: HEAR) 12.3% LOWER; reported Q4 EPS of $1.33, $0.02 better than the analyst estimate of $1.31. Revenue for the quarter came in at $111.3 million versus the consensus estimate of $110.2 million. Turtle Beach sees Q1 2019 EPS of $0.05, versus the consensus of $0.09. Turtle Beach sees Q1 2019 revenue of $42 million, versus the consensus of $34.84 million. Turtle Beach sees FY2019 EPS of $0.90-$1.10, versus the consensus of $1.64. Turtle Beach sees FY2019 revenue of $240-248 million, versus the consensus of $243.14 million.

Catasys (NASDAQ: CATS) 11.2% HIGHER; reported Q4 EPS of ($0.09), $0.17 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $5.6 million versus the consensus estimate of $4.89 million. Catasys sees FY2019 revenue of $35 million, versus the consensus of $34.63 million.

Tilly's, Inc. (NYSE: TLYS) 7.8% LOWER; reported Q4 EPS of $0.27, $0.02 better than the analyst estimate of $0.25. Revenue for the quarter came in at $170.6 million versus the consensus estimate of $169 million. Tilly's, Inc. sees Q1 2019 EPS of ($0.01)-$0.03, versus the consensus of $0.07. Tilly's, Inc. sees Q1 2019 revenue of $128-130 million, versus the consensus of $131.7 million.

Mammoth Energy Services (NASDAQ: TUSK) 7.6% LOWER; reported Q4 EPS of $1.51, $0.78 better than the analyst estimate of $0.73. Revenue for the quarter came in at $278.2 million versus the consensus estimate of $358.37 million.

Organogenesis Holdings Inc. (Nasdaq: ORGO) 5.6% HIGHER; announced a new credit agreement with Silicon Valley Bank, the lead agent, and MidCap Financial

Zumiez, Inc. (NASDAQ: ZUMZ) 5.4% LOWER; reported Q4 EPS of $1.18, $0.07 better than the analyst estimate of $1.11. Revenue for the quarter came in at $304.6 million versus the consensus estimate of $305.55 million. Zumiez, Inc. sees Q1 2019 EPS of ($0.13)-($0.07), versus the consensus of ($0.05). Zumiez, Inc. sees Q1 2019 revenue of $202-206 million, versus the consensus of $213 million.

Broadcom (NASDAQ: AVGO) 5.2% HIGHER; reported Q1 EPS of $5.55, $0.32 better than the analyst estimate of $5.23. Revenue for the quarter came in at $5.79 billion versus the consensus estimate of $5.82 billion.

Pivotal Software, Inc. (NYSE: PVTL) 4% LOWER; reported Q4 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $169.2 million versus the consensus estimate of $169.82 million. Pivotal Software, Inc. sees Q1 2020 EPS of ($0.06)-($0.05), versus the consensus of ($0.06). Pivotal Software, Inc. sees Q1 2020 revenue of $183-185 million, versus the consensus of $191.06 million. Pivotal Software, Inc. sees FY2020 EPS of ($0.15)-($0.13), versus the consensus of ($0.16). Pivotal Software, Inc. sees FY2020 revenue of $798-806 million, versus the consensus of $813 million.

Zillow Group (NASDAQ: ZG) 4% LOWER; Barclays downgraded from Equalweight to Underweight with a price target of $32.00.

Oracle (NYSE: ORCL) 3.9% LOWER; reported Q3 EPS of $0.87, $0.03 better than the analyst estimate of $0.84. Revenue for the quarter came in at $9.6 billion versus the consensus estimate of $9.59 billion. Sees Q4 revenue flat to down 2% in U.S. dollars. It sees Q4 EPS of $1.05-$1.09 in constant currency. (**Consensus sees Q4 EPS of $1.05 on revenue of $11.15 billion)

Ulta Salon (NASDAQ: ULTA) 3.4% HIGHER; reported Q4 EPS of $3.61, $0.05 better than the analyst estimate of $3.56. Revenue for the quarter came in at $2.12 billion versus the consensus estimate of $2.11 billion. Comparable Sales Increased 9.4%. Ulta Salon sees FY2019 EPS of $12.65-$12.85, versus the consensus of $12.74.

ViewRay (NASDAQ: VRAY) 2.7% LOWER; reported Q4 EPS of ($0.17), $0.06 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $20.7 million versus the consensus estimate of $20.38 million. ViewRay sees FY2019 revenue of $111-124 million, versus the consensus of $124.33 million.

Adobe Systems (NASDAQ: ADBE) 2.3% LOWER; reported Q1 EPS of $1.71, $0.09 better than the analyst estimate of $1.62. Revenue for the quarter came in at $2.6 billion versus the consensus estimate of $2.55 billion. Adobe Systems sees Q2 2019 EPS of $1.77, versus the consensus of $1.88. Adobe Systems sees Q2 2019 revenue of $2.7 billion, versus the consensus of $2.72 billion. Adobe Systems sees FY2019 EPS of $7.80, versus the consensus of $7.77. Adobe Systems sees FY2019 revenue of $11.15 billion, versus the consensus of $11.16 billion.

Fluidigm Corporation (NASDAQ: FLDM) 2.1% HIGHER; UBS initiates coverage on with a Neutral rating and a price target of $14.00.

Facebook (NASDAQ: FB) 1.8% LOWER; Chief Product Officer Chris Cox to Leave

Categories

Special Reports